comscoreGenetic Testing

Genetic Testing

49 Research news
 
 
Article
Study Suggests Breast Cancer Screening Options for Women With ATM, CHEK2, and PALB2 Mutations

Women with ATM, CHEK2, or PALB2 mutations may benefit from starting annual breast cancer screening with MRI between the ages and 30 to 35 and an annual MRI and mammogram starting at age 40.

 
Article
Genetic Test Results Can Offer Peace of Mind

Women at high risk for breast cancer who had genetic testing benefited psychologically from knowing the results of the test.

 
Article
Women With Abnormal BRCA Gene Have Higher Risk of New Cancer in Opposite Breast

Research shows that women with an abnormal BRCA1 or BRCA2 gene who've been diagnosed with breast cancer have a higher risk of being diagnosed with a new, different cancer in the opposite breast compared to women without an abnormal BRCA1 or BRCA2 gene.

 
Article
Women With Abnormal BRCA1 Gene Who Develop Breast Cancer Live Just as Long as Diagnosed Women Without BRCA1 Mutation

Research suggests that just as many younger women with an abnormal BRCA1 gene who develop breast cancer are alive 10 years after diagnosis as younger women without an abnormal BRCA1 gene who develop breast cancer.

 
Article
Multi-Gene Genetic Tests Don't Cause More Worry Than BRCA Testing Alone in Women Diagnosed With Breast Cancer

The results from panel genetic tests looking at a dozen or more genes can be more complex, but these results are not causing women diagnosed with breast cancer more worry than older tests looking at only one or two genes.

 
Article
Unclear Explanation of Genetic Testing Results Seems to Affect Treatment Decisions

A study suggests that genetic test results are not being clearly communicated to women and may be causing them to opt for breast cancer treatment that is more aggressive than they need.

 
Article
Veliparib Maintenance After Chemo Slightly Improves Outcomes for Metastatic HER2-Negative Breast Cancer With BRCA Mutations

People diagnosed with metastatic HER2-negative breast cancer with a BRCA1 or BRCA2 mutation treated with experimental veliparib and chemotherapy lived about 2 months longer without the cancer growing if they continued on veliparib after stopping chemotherapy.

 
Article
Pregnancy After Breast Cancer Seems Safe for Women With BRCA Mutation

Women with a BRCA1 or BRCA2 mutation who become pregnant after being treated for breast cancer don't have a higher risk of recurrence and their babies are healthy.

 
Article
BRCA1 Mutation Linked to Higher Risk of Specific Type of Uterine Cancer

A study strongly suggests that women with a BRCA1 mutation have a slightly higher risk of an uncommon but aggressive type of uterine cancer.

Jul 5, 2016 | Diagnosis, Genetic Testing and Surgery
 
Article
Lynparza Approved to Treat Metastatic HER2-Negative Breast Cancer in Women With BRCA Mutations

On Jan. 12, 2018, the FDA approved Lynparza to treat metastatic HER2-negative breast cancer in women with a BRCA1 or BRCA2 mutation.

 
Article
Women With Abnormal BRCA1 Gene Have Worse Prognosis Than Women With Abnormal BRCA2 Gene

A new study suggests that having an abnormal BRCA2 gene has a better prognosis 5 years after diagnosis than having an abnormal BRCA1 gene.

 
Article
Risk of Breast, Ovarian Cancer May Vary Depending on Type and Location of BRCA Mutation

A study suggests that a woman's risk of breast and ovarian cancer may vary depending on the type of mutation a woman has and where the mutation is located on the BRCA1 or BRCA2 gene.

 
Article
MRI Twice per Year May Be Better Than Annual Mammogram for Finding Early Breast Cancers in High-Risk Women

A study suggests that breast cancer screening with MRI twice per year is better than one mammogram per year for finding breast cancer early in young women with a high risk of breast cancer.

 
Article
BRCA1 Mutation Linked to Fewer Eggs in Ovaries

A study found that women with a BRCA1 mutation had levels of a hormone that indicates how many eggs are left in the ovaries that were 25% lower than women who didn't have the mutation.

 
Article
If Relatives Have Abnormal Breast Cancer Gene, Women Who Test Negative Have Higher Risk

The results of a new study are particularly important for women with a family member who has an abnormal BRCA1 or BRCA2 gene. Even though the women in the study tested negative for an abnormal BRCA1 or...

Oct 31, 2006 | Diagnosis and Genetic Testing
 
Article
Parents Often Tell Kids About Abnormal Genes Before Interventions Needed

New research suggests that parents should wait until their children reach early adulthood before talking to them about abnormal genetic test results.

 
Article
New Type of Targeted Therapy May Help Treat Triple-Negative Disease

Experimental targeted therapy medicines -- called PARP inhibitors -- may make chemotherapy work better against aggressive forms of breast cancer and also may be able to treat breast cancer alone, without chemotherapy.

 
Article
Diagnosed Women With Abnormal Breast Cancer Gene Have Higher Risk of New Cancer in Opposite Breast

Research suggests that women with an abnormal BRCA1 or BRCA2 gene who have been diagnosed with breast cancer are 4 times more likely to be diagnosed with a new cancer in the opposite breast compared to women without an abnormal breast cancer gene diagnosed with breast cancer.

 
Article
Abnormal BRCA1 Gene Linked to Worse Outcomes Than Abnormal BRCA2 Gene

A study suggests women with an abnormal BRCA1 gene have worse breast cancer survival and recurrence rates than women with an abnormal BRCA2 gene or women who don't have either abnormal gene.

 
Article
Experimental Targeted Therapy May Help Treat People With Advanced-Stage Cancer Due to Abnormal BRCA Gene

A study found that more than 25% of people with an abnormal BRCA1 or BRCA2 gene being treated for advanced-stage breast, ovarian, pancreatic, or prostate cancer got some benefit from olaparib, an experimental targeted therapy medicine.

 
Article
Women With Abnormal BRCA1 Gene Benefit From Ovary Removal

Women with an abnormal BRCA1 gene diagnosed with breast cancer are more likely to survive if they have their ovaries removed.

 
Article
Experimental Talazoparib Seems Better Than Chemotherapy for Metastatic HER2-Negative Disease in Women With a BRCA Mutation

The targeted therapy talazoparib resulted in longer progression-free survival compared to chemotherapy in women with a BRCA1 or BRCA2 mutation diagnosed with metastatic HER2-negative breast cancer.

 
Article
Why Are Women With BRCA1 and BRCA2 Mutations Being Diagnosed at Younger Age?

A study suggests that environmental and lifestyle factors are causing women with a BRCA1 or BRCA2 mutation to be diagnosed with breast and/or ovarian cancer at younger ages.

Apr 7, 2016 | Genetic Testing and Risk Factors
 
Article
Advanced-Stage, Triple-Negative Breast Cancer in Women With BRCA1/2 Mutation Seems to Respond Better to Carboplatin Than Taxotere

Women diagnosed with advanced-stage, triple-negative breast cancer who have a BRCA1 or BRCA2 mutation have a better response to carboplatin than Taxotere.

Showing 24 of 49